Victory Capital Management
RIGL icon

Victory Capital Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Victory Capital Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,264
Closed -$33.5K – 2527
2024
Q1 		$33.5K Sell
2,264
-50
-2% -$674 ﹤0.01% 2409
2023
Q4 		$33.6K Buy
2,314
+436
+23% +$4.46K ﹤0.01% 2475
2023
Q3 		$20.3K Buy
1,878
+4
+0.2% +$48 ﹤0.01% 2446
2023
Q2 		$24.2K Sell
1,874
-43
-2% -$581 ﹤0.01% 2436
2023
Q1 		$25.3K Sell
1,917
-25
-1% -$397 ﹤0.01% 2493
2022
Q4 		$29.1K Sell
1,942
-1
-0.1% -$9 ﹤0.01% 2494
2022
Q3 		$23K Buy
1,943
+58
+3% +$784 ﹤0.01% 2616
2022
Q2 		$21K Sell
1,885
-2
-0.1% -$40 ﹤0.01% 2613
2022
Q1 		$45K Sell
1,887
-29
-2% -$785 ﹤0.01% 2605
2021
Q4 		$51K Sell
1,916
-57
-3% -$1.72K ﹤0.01% 2639
2021
Q3 		$72K Sell
1,973
-65
-3% -$2.56K ﹤0.01% 2656
2021
Q2 		$88K Sell
2,038
-145
-7% -$5.47K ﹤0.01% 2613
2021
Q1 		$75K Sell
2,183
-53
-2% -$2.1K ﹤0.01% 2629
2020
Q4 		$78K Buy
2,236
+114
+5% +$3.3K ﹤0.01% 2432
2020
Q3 		$51K Sell
2,122
-117
-5% -$2.87K ﹤0.01% 2388
2020
Q2 		$41K Sell
2,239
-2,375
-51% -$42.7K ﹤0.01% 2409
2020
Q1 		$72K Buy
4,614
+96
+2% +$2.04K ﹤0.01% 2636
2019
Q4 		$97K Buy
4,518
+2,200
+95% +$45.3K ﹤0.01% 2548
2019
Q3 		$43K Buy
+2,318
New +$47.9K ﹤0.01% 2748
2019
Q2 		– Sell
-812
Closed -$21K – 1855
2019
Q1 		$21K Hold
812
– – ﹤0.01% 1741
2018
Q4 		$19K Hold
812
– – ﹤0.01% 1742
2018
Q3 		$26K Buy
812
+107
+15% +$3.21K ﹤0.01% 1744
2018
Q2 		$20K Hold
705
– – ﹤0.01% 1795
2018
Q1 		$25K Sell
705
-460
-39% -$18.4K ﹤0.01% 1783
2017
Q4 		$45K Hold
1,165
– – ﹤0.01% 1747
2017
Q3 		$30K Hold
1,165
– – ﹤0.01% 1763
2017
Q2 		$32K Buy
1,165
+466
+67% +$12.8K ﹤0.01% 1752
2017
Q1 		$23K Hold
699
– – ﹤0.01% 1764
2016
Q4 		$17K Buy
699
+39
+6% +$1.12K ﹤0.01% 1767
2016
Q3 		$24K Buy
+660
New +$18.9K ﹤0.01% 1742

Other funds holding RIGL

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Victory Capital Management's RIGL Position: Q2 2024 in Review

Victory Capital Management sold out of Rigel Pharmaceuticals (RIGL) in Q2 2024, closing a stake of 2,264 shares — an estimated $33.5K sold.

Victory Capital Management first reported a position in RIGL in Q3 2016 and held it in 30 quarters. The position peaked at $97K in Q4 2019. 91 funds tracked by Wall St. Rank hold RIGL as of Q2 2024.

  • Victory Capital Management reported no remaining Rigel Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Victory Capital Management sold 2,264 Rigel Pharmaceuticals shares in Q2 2024, an estimated $33.5K.
  • Victory Capital Management first reported a position in Rigel Pharmaceuticals in Q3 2016 and held it in 30 quarters.
  • Victory Capital Management's Rigel Pharmaceuticals position peaked at $97K in Q4 2019.
  • 91 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2024.

Based on Victory Capital Management's 13F filing for Q2 2024, filed 5 Aug 2024.